Revenue FY2025
—
Net Income
$(83.0M)
EPS (Basic)
$-0.13
Net Margin
—
ROE
-37.0%
Total Equity
$226.0M
Shares Out
642M
GERON CORP — Pharmaceutical Preparations. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2009–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.
Revenue & Net Income (10Y)
Margin Trends
Investor Ownership · 3 funds in our universe
FundPosition Value% of AUMQoQ ChgWeight
RA Capital Management
RA Capital Management
$54.8M
0.3%
(32.9%)
Vivo Capital
Vivo Capital
$11.1M
0.2%
—
Alps Advisors
Alps Advisors
$0.8M
0.0%
+24.9%
Insider Transactions
Reading stored insider transactions…